VEGF Trap

BIOLOGICAL4 trials

Sponsors

Regeneron Pharmaceuticals, National Cancer Institute (NCI), Vanderbilt-Ingram Cancer Center

Conditions

LeukemiaMacular DegenerationMetastatic Renal Cell CarcinomaNeovascular Age Related Macular Degeneration

Phase 1

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

CompletedNCT00320775

Regeneron PharmaceuticalsMacular Degeneration

Start: 2005-06-30End: 2008-08-31Updated: 2015-03-18

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

CompletedNCT00383370

Regeneron PharmaceuticalsNeovascular Age Related Macular Degeneration

Start: 2006-10-31End: 2008-07-31Updated: 2011-04-21

Phase 2

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

CompletedNCT00357760

National Cancer Institute (NCI)Metastatic Renal Cell Carcinoma

Start: 2007-12-31End: 2015-10-31Updated: 2017-06-23

A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia

WithdrawnNCT00601991

Vanderbilt-Ingram Cancer CenterLeukemia

Start: 2007-03-31End: 2009-10-31Updated: 2013-04-02

Related Papers

Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805].

Journal of Clinical Oncology2015-05-205 citations